Novartis' Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggest

Novartis' Rhapsido cuts MS relapse rates and shows a clean safety profile in Phase 3 trials; Jefferies sees peak sales above $3B.

Raccontata daendpoints.news